Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases: A CALIBER Cohort Study

Anoop Dinesh Shah, Spiros Denaxas, Owen Nicholas, Aroon D Hingorani, Harry Hemingway, Anoop Dinesh Shah, Spiros Denaxas, Owen Nicholas, Aroon D Hingorani, Harry Hemingway

Abstract

Background: Neutrophil counts are a ubiquitous measure of inflammation, but previous studies on their association with cardiovascular disease (CVD) were limited by small numbers of patients or a narrow range of endpoints.

Objectives: This study investigated associations of clinically recorded neutrophil counts with initial presentation for a range of CVDs.

Methods: We used linked primary care, hospitalization, disease registry, and mortality data in England. We included people 30 years or older with complete blood counts performed in usual clinical care and no history of CVD. We used Cox models to estimate cause-specific hazard ratios (HRs) for 12 CVDs, adjusted for cardiovascular risk factors and acute conditions affecting neutrophil counts (such as infections and cancer).

Results: Among 775,231 individuals in the cohort, 154,179 had complete blood counts performed under acute conditions and 621,052 when they were stable. Over a median 3.8 years of follow-up, 55,004 individuals developed CVD. Adjusted HRs comparing neutrophil counts 6 to 7 versus 2 to 3 × 109/l (both within the 'normal' range) showed strong associations with heart failure (HR: 2.04; 95% confidence interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI: 1.72 to 2.21), unheralded coronary death (HR: 1.78; 95% CI: 1.51 to 2.10), abdominal aortic aneurysm (HR: 1.72; 95% CI: 1.34 to 2.21), and nonfatal myocardial infarction (HR: 1.58; 95% CI: 1.42 to 1.76). These associations were linear, with greater risk even among individuals with neutrophil counts of 3 to 4 versus 2 to 3 × 109/l. There was a weak association with ischemic stroke (HR: 1.36; 95% CI: 1.17 to 1.57), but no association with stable angina or intracerebral hemorrhage.

Conclusions: Neutrophil counts were strongly associated with the incidence of some CVDs, but not others, even within the normal range, consistent with underlying disease mechanisms differing across CVDs. (White Blood Cell Counts and Onset of Cardiovascular Diseases: a CALIBER Study [CALIBER]; NCT02014610).

Keywords: disease mechanisms; electronic health records; epidemiology; incidence; inflammation.

Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
Cumulative Incidence Curves For cardiovascular presentations among people without prior cardiovascular disease (CVD), crude cumulative incidence curves are shown for the highest and lowest categories of neutrophil count within the normal range. An artefact of imprecise coding rather than a clinical diagnosis, ‘nonspecific coronary disease’ was combined with unstable angina. Similarly, nonspecific stroke was combined with ischemic stroke. The plots show that, for myocardial infarction, heart failure, ischemic stroke, peripheral arterial disease (PAD), and abdominal aortic aneurysm, the incidence was greater among people with higher neutrophil counts.
Figure 2
Figure 2
Association of Neutrophil Count With Initial CVD Presentation Neutrophil count categories influenced cause-specific adjusted hazard ratios for cardiovascular presentations among people without prior cardiovascular disease (CVD). Hazard ratios were adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure (SBP), blood pressure medication, body mass index (BMI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), statin use, estimated glomerular filtration rate (eGFR), atrial fibrillation (AF), autoimmune conditions, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), cancer, and acute conditions at the time of blood testing. Shaded = normal range. *p 

Figure 3

CVD and Neutrophil Counts by…

Figure 3

CVD and Neutrophil Counts by Clinical State at Blood Sampling Hazard ratios for…

Figure 3
CVD and Neutrophil Counts by Clinical State at Blood Sampling Hazard ratios for initial presentation of CVDs by neutrophil count varied by clinical state at the time of blood sampling. ‘Mean of 2 stable’ refers to the mean of 2 consecutive neutrophil counts performed in a stable clinical state. Hazard ratios are adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking, diabetes, SBP, blood pressure medication, BMI, total cholesterol, HDL-C, statin use, eGFR, AF, autoimmune conditions, IBD, COPD, and cancer. *p 

Central Illustration

Neutrophil Counts and CVDs Potential…

Central Illustration

Neutrophil Counts and CVDs Potential causal pathways are depicted linking chronic inflammation, neutrophil…

Central Illustration
Neutrophil Counts and CVDs Potential causal pathways are depicted linking chronic inflammation, neutrophil counts, and onset of cardiovascular diseases (CVD). Environmental and behavioral risk factors such as smoking, air pollution, and physical inactivity contribute to chronic inflammation. An inflammatory state results in a higher neutrophil count, which may be causally linked with increased risk of certain cardiovascular conditions.
Comment in
Similar articles
Cited by
References
    1. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212. - PubMed
    1. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–175. - PubMed
    1. Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–1320. - PMC - PubMed
    1. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214–1224. - PMC - PubMed
    1. Adamsson Eryd S., Smith J.G., Melander O. Incidence of coronary events and case fatality rate in relation to blood lymphocyte and neutrophil counts. Arterioscler Thromb Vasc Biol. 2012;32:533–539. - PubMed
Show all 31 references
MeSH terms
Associated data
Related information
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 3
Figure 3
CVD and Neutrophil Counts by Clinical State at Blood Sampling Hazard ratios for initial presentation of CVDs by neutrophil count varied by clinical state at the time of blood sampling. ‘Mean of 2 stable’ refers to the mean of 2 consecutive neutrophil counts performed in a stable clinical state. Hazard ratios are adjusted for age, sex, socioeconomic deprivation, ethnicity, smoking, diabetes, SBP, blood pressure medication, BMI, total cholesterol, HDL-C, statin use, eGFR, AF, autoimmune conditions, IBD, COPD, and cancer. *p 

Central Illustration

Neutrophil Counts and CVDs Potential…

Central Illustration

Neutrophil Counts and CVDs Potential causal pathways are depicted linking chronic inflammation, neutrophil…

Central Illustration
Neutrophil Counts and CVDs Potential causal pathways are depicted linking chronic inflammation, neutrophil counts, and onset of cardiovascular diseases (CVD). Environmental and behavioral risk factors such as smoking, air pollution, and physical inactivity contribute to chronic inflammation. An inflammatory state results in a higher neutrophil count, which may be causally linked with increased risk of certain cardiovascular conditions.
Central Illustration
Central Illustration
Neutrophil Counts and CVDs Potential causal pathways are depicted linking chronic inflammation, neutrophil counts, and onset of cardiovascular diseases (CVD). Environmental and behavioral risk factors such as smoking, air pollution, and physical inactivity contribute to chronic inflammation. An inflammatory state results in a higher neutrophil count, which may be causally linked with increased risk of certain cardiovascular conditions.

References

    1. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204–212.
    1. Kolaczkowska E., Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13:159–175.
    1. Emerging Risk Factors Collaboration C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–1320.
    1. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214–1224.
    1. Adamsson Eryd S., Smith J.G., Melander O. Incidence of coronary events and case fatality rate in relation to blood lymphocyte and neutrophil counts. Arterioscler Thromb Vasc Biol. 2012;32:533–539.
    1. Pfister R., Sharp S.J., Luben R. Differential white blood cell count and incident heart failure in men and women in the EPIC-Norfolk study. Eur Heart J. 2012;33:523–530.
    1. Zia E., Melander O., Bjorkbacka H. Total and differential leucocyte counts in relation to incidence of stroke subtypes and mortality: a prospective cohort study. J Intern Med. 2012;272:298–304.
    1. Denaxas S.C., George J., Herrett E. Data resource profile: Cardiovascular Disease Research Using Linked Bespoke Studies and Electronic Health Records (CALIBER) Int J Epidemiol. 2012;41:1625–1638.
    1. George J., Rapsomaniki E., Pujades-Rodriguez M. How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1 937 360 people. Circulation. 2015;132:1320–1328.
    1. Pujades-Rodriguez M., George J., Shah A.D. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1 937 360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol. 2015;44:129–141.
    1. Rapsomaniki E., Timmis A., George J. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1⋅25 million people. Lancet. 2014;383:1899–1911.
    1. Pujades-Rodriguez M., Timmis A., Stogiannis D. Socioeconomic deprivation and the incidence of 12 cardiovascular diseases in 1.9 million women and men: implications for risk prediction and prevention. PLoS One. 2014;9:e104671.
    1. Shah A.D., Langenberg C., Rapsomaniki E. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015;3:105–113.
    1. Shah A.D., Denaxas S., Nicholas O. Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases: a CALIBER cohort study. Open Heart. 2016;3:e000477.
    1. Herrett E., Shah A.D., Boggon R. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ. 2013;346:f2350.
    1. Lim E.M., Cembrowski G., Cembrowski M. Race-specific WBC and neutrophil count reference intervals. Int J Lab Haematol. 2010;32:590–597.
    1. Jarvik G, Crosslin D, Group Health Cooperative. White Blood Cell Indices. PheKB; 2012. Available at: . Accessed December 13, 2016.
    1. Shah A.D., Bartlett J.W., Carpenter J.R. Comparison of random forest and parametric imputation models when imputing missing data using MICE: a CALIBER study. Am J Epidemiol. 2014;179:764–774.
    1. Borissoff J.I., Cate H.T. From neutrophil extracellular traps release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost. 2011;9:1791–1794.
    1. Madjid M., Fatemi O. Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Tex Heart Inst J. 2013;40:17–29.
    1. von Vietinghoff S., Ley K. Homeostatic regulation of blood neutrophil counts. J Immunol. 2008;181:5183–5188.
    1. Crosslin D.R., McDavid A., Weston N. Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum Genet. 2012;131:639–652.
    1. Nidorf S.M., Eikelboom J.W., Budgeon C.A. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–406.
    1. Everett B.M., Pradhan A.D., Solomon D.H. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166:199–207.e15.
    1. Ridker P.M., Thuren T., Zalewski A. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Am Heart J. 2011;162:597–605.
    1. Jensen E.J., Pedersen B., Frederiksen R. Prospective study on the effect of smoking and nicotine substitution on leucocyte blood counts and relation between blood leucocytes and lung function. Thorax. 1998;53:784–789.
    1. ESC Working Group on Thrombosis, European Association for Cardiovascular Prevention and Rehabilitation. ESC Heart Failure Association Expert position paper on air pollution and cardiovascular disease. Eur Heart J. 2015;36:83–93.
    1. Chen Y.W., Apostolakis S., Lip G.Y.H. Exercise-induced changes in inflammatory processes: Implications for thrombogenesis in cardiovascular disease. Ann Med. 2014;46:439–455.
    1. Nakamura K., Fuster J.J., Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63:250–259.
    1. Tonetti M.S., D’Aiuto F., Nibali L. Treatment of periodontitis and endothelial function. N Engl J Med. 2007;356:911–920.
    1. Goff D.C., Jr., Lloyd-Jones D.M., Bennett G. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol. 2014;63:2935–2959.

Source: PubMed

3
Předplatit